| Drugs by Condition |  |
Skin and Structure Infection Medications
Drugs (by generic name) associated with Skin and Structure Infection
The following drugs and medications are in some way related to, or used in the treatment of Skin and Structure Infection. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
See also...
Skin and Structure Infection Medications in the Pipeline
Dalbavancin
- September 9, 2008 - Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
- December 21, 2007 - Pfizer Receives Approvable Letter from FDA for Dalbavancin
- June 2, 2005 - Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark Office
- May 11, 2005 - Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug Application
- February 24, 2005 - Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue Infections
- December 21, 2004 - Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
ceftobiprole
- September 3, 2009 - FDA accepts for review the Complete Response submission to ceftobiprole NDA
- November 26, 2008 - FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
- September 15, 2008 - FDA accepts for review the Complete Response to ceftobiprole NDA Approvable Letter
- March 18, 2008 - FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
- February 13, 2008 - FDA Published Today That It Will Not Hold an Advisory Committee Meeting on Ceftobiprole in the Treatment of Complicated Skin and Skin Structure Infections
- January 10, 2008 - Basilea Announces Review of Ceftobiprole NDA at FDA Anti-Infective Drugs Advisory Committee Meeting
- July 18, 2007 - U.S. FDA and European EMEA Accept Registration Applications for Ceftobiprole, Novel Anti-MRSA Broad-Spectrum Cephalosporin
- May 18, 2007 - New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
Oritavancin
- December 9, 2008 - FDA Issues Complete Response Letter for Oritavancin
- October 15, 2008 - Targanta Announces Review of Oritavancin at FDA Anti-Infective Drugs Advisory Committee Meeting
- April 9, 2008 - Targanta Announces FDA Acceptance of Oritavancin New Drug Application
- February 11, 2008 - Targanta Submits Oritavancin New Drug Application
Iclaprim
- January 20, 2009 - FDA Issues Complete Response Letter for Iclaprim
- November 21, 2008 - Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
- October 14, 2008 - Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
- May 16, 2008 - Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
- March 19, 2008 - Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
